These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6784933)

  • 1. Shedding of tumor cell surface membranes.
    Liepins A; Hillman AJ
    Cell Biol Int Rep; 1981 Jan; 5(1):15-26. PubMed ID: 6784933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low temperature-induced cell surface membrane vesicle shedding is associated with DNA fragmentation.
    Liepins A; Younghusband HB
    Exp Cell Res; 1985 Dec; 161(2):525-32. PubMed ID: 2998839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spin labeling studies of the interactions of P815 mouse mastocytoma cells with antiserum to histocompatibility antigens, H-2d.
    Merritt MV; Loughman E
    Immunopharmacology; 1979 Jul; 1(4):301-14. PubMed ID: 95572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible role of microtubules in tumor cell surface membrane shedding, permeability, and lympholysis.
    Liepins A
    Cell Immunol; 1983 Feb; 76(1):120-8. PubMed ID: 6299587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
    Carayanniotis G; Halloran PF
    Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The blocking activity of antisera raised to either tumor antigens or alloantigens in cytotoxicity assays using syngeneic or allogeneic killer cells on the P815 murine mastocytoma target.
    Al-Rammahy AK; Levy JG
    Cell Immunol; 1980 Dec; 56(2):338-46. PubMed ID: 6781763
    [No Abstract]   [Full Text] [Related]  

  • 7. Oxygen consumption by tumor cells during membrane vesicle shedding.
    Liepins A; Jayasinghe D
    Cell Biol Int Rep; 1985 May; 9(5):501-11. PubMed ID: 2990740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and partial characterization of a tumor-associated antigen of the P815 mastocytoma of DBA/2 mice.
    Al-Rammahy AK; Levy JG; Jackson AL
    J Immunol; 1980 Jan; 124(1):143-50. PubMed ID: 6765966
    [No Abstract]   [Full Text] [Related]  

  • 9. Systemic immune unresponsiveness induced in adult mice by anterior chamber presentation of minor histocompatibility antigens.
    Streilein JW; Niederkorn JY; Shadduck JA
    J Exp Med; 1980 Oct; 152(4):1121-5. PubMed ID: 6775039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic changes of DBA/2J mastocytoma cells when grown in the BALB/c mouse.
    Wolf JE; Faanes RB; Choi YS
    J Natl Cancer Inst; 1977 May; 58(5):1407-12. PubMed ID: 67213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells.
    Williams BA; Makrigiannis AP; Blay J; Hoskin DW
    Int J Cancer; 1997 Nov; 73(3):416-23. PubMed ID: 9359490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
    Maryanski JL; Boon T
    Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid vesicles as carriers for introducing materials into cultured cells: influence of vesicle lipid composition on mechanism(s) of vesicle incorporation into cells.
    Poste G; Papahadjopoulos D
    Proc Natl Acad Sci U S A; 1976 May; 73(5):1603-7. PubMed ID: 818640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
    Streilein JW; Niederkorn JY
    J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and properties of antisera directed against antigens of the P-815 mastocytoma cell not shared by its syngeneic host, the DBA/2 mouse.
    Bertschmann M; Clemetson KJ; Lüscher EF
    Eur J Cancer (1965); 1976 Apr; 12(4):255-62. PubMed ID: 60238
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response.
    Maryanski JL; Van Snick J; Cerottini JC; Boon T
    Eur J Immunol; 1982 May; 12(5):401-6. PubMed ID: 6178607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.
    Boon T; Van Snick J; Van Pel A; Uyttenhove C; Marchand M
    J Exp Med; 1980 Nov; 152(5):1184-93. PubMed ID: 6776227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815.
    Bilsborough J; Van Pel A; Uyttenhove C; Boon T; Van den Eynde BJ
    J Immunol; 1999 Mar; 162(6):3534-40. PubMed ID: 10092811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Humoral mechanisms of in vitro inhibition of mouse lymphocyte immunoreactivity by mastocytoma P815 cells].
    Medvedev AE
    Biull Eksp Biol Med; 1988 Jun; 105(6):701-3. PubMed ID: 2968820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.